Structuring the new product development pipeline

Ming Ding, Jehoshua Eliashberg

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

In many new product development (NPD) situations, the development process is characterized by uncertainty, and no single development approach will necessarily lead to a successful product. To increase the likelihood of having at least one successful product, multiple approaches may be simultaneously funded at the various NPD stages. The managerial challenge is to construct ex ante an appropriate NPD pipeline by choosing the right number of approaches to be funded at each stage. This so-called pipeline problem is also present in, among others, advertising copy selection and new products test markets problems. We describe here a normative model for structuring pipelines for such situations. The optimal structure of the pipeline is driven by the cost of the development approach, its probability of survival, and the expected profitability. We illustrate the workability and implications of the model by applying it to some real-world scenarios in the pharmaceutical industry, and by comparing its normative pipeline recommendations against actual pipelines. Our results suggest that, for the cases we studied, firms tend to use narrower pipelines for their new drug development than they should, and thereby they underspend on research and development. We also present general qualitative insights for one- and two-stage NPD optimal pipeline structures.

Original languageEnglish (US)
Pages (from-to)343-363
Number of pages21
JournalManagement Science
Volume48
Issue number3
DOIs
StatePublished - Mar 2002

Fingerprint

New product development
Pharmaceutical industry
Development process
Scenarios
Development stage
Costs
Drug development
Uncertainty
New products
Profitability

All Science Journal Classification (ASJC) codes

  • Strategy and Management
  • Management Science and Operations Research

Cite this

Ding, Ming ; Eliashberg, Jehoshua. / Structuring the new product development pipeline. In: Management Science. 2002 ; Vol. 48, No. 3. pp. 343-363.
@article{218c6b6a4734406ba2e0ff40b9dce7b4,
title = "Structuring the new product development pipeline",
abstract = "In many new product development (NPD) situations, the development process is characterized by uncertainty, and no single development approach will necessarily lead to a successful product. To increase the likelihood of having at least one successful product, multiple approaches may be simultaneously funded at the various NPD stages. The managerial challenge is to construct ex ante an appropriate NPD pipeline by choosing the right number of approaches to be funded at each stage. This so-called pipeline problem is also present in, among others, advertising copy selection and new products test markets problems. We describe here a normative model for structuring pipelines for such situations. The optimal structure of the pipeline is driven by the cost of the development approach, its probability of survival, and the expected profitability. We illustrate the workability and implications of the model by applying it to some real-world scenarios in the pharmaceutical industry, and by comparing its normative pipeline recommendations against actual pipelines. Our results suggest that, for the cases we studied, firms tend to use narrower pipelines for their new drug development than they should, and thereby they underspend on research and development. We also present general qualitative insights for one- and two-stage NPD optimal pipeline structures.",
author = "Ming Ding and Jehoshua Eliashberg",
year = "2002",
month = "3",
doi = "10.1287/mnsc.48.3.343.7727",
language = "English (US)",
volume = "48",
pages = "343--363",
journal = "Management Science",
issn = "0025-1909",
publisher = "INFORMS Inst.for Operations Res.and the Management Sciences",
number = "3",

}

Structuring the new product development pipeline. / Ding, Ming; Eliashberg, Jehoshua.

In: Management Science, Vol. 48, No. 3, 03.2002, p. 343-363.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Structuring the new product development pipeline

AU - Ding, Ming

AU - Eliashberg, Jehoshua

PY - 2002/3

Y1 - 2002/3

N2 - In many new product development (NPD) situations, the development process is characterized by uncertainty, and no single development approach will necessarily lead to a successful product. To increase the likelihood of having at least one successful product, multiple approaches may be simultaneously funded at the various NPD stages. The managerial challenge is to construct ex ante an appropriate NPD pipeline by choosing the right number of approaches to be funded at each stage. This so-called pipeline problem is also present in, among others, advertising copy selection and new products test markets problems. We describe here a normative model for structuring pipelines for such situations. The optimal structure of the pipeline is driven by the cost of the development approach, its probability of survival, and the expected profitability. We illustrate the workability and implications of the model by applying it to some real-world scenarios in the pharmaceutical industry, and by comparing its normative pipeline recommendations against actual pipelines. Our results suggest that, for the cases we studied, firms tend to use narrower pipelines for their new drug development than they should, and thereby they underspend on research and development. We also present general qualitative insights for one- and two-stage NPD optimal pipeline structures.

AB - In many new product development (NPD) situations, the development process is characterized by uncertainty, and no single development approach will necessarily lead to a successful product. To increase the likelihood of having at least one successful product, multiple approaches may be simultaneously funded at the various NPD stages. The managerial challenge is to construct ex ante an appropriate NPD pipeline by choosing the right number of approaches to be funded at each stage. This so-called pipeline problem is also present in, among others, advertising copy selection and new products test markets problems. We describe here a normative model for structuring pipelines for such situations. The optimal structure of the pipeline is driven by the cost of the development approach, its probability of survival, and the expected profitability. We illustrate the workability and implications of the model by applying it to some real-world scenarios in the pharmaceutical industry, and by comparing its normative pipeline recommendations against actual pipelines. Our results suggest that, for the cases we studied, firms tend to use narrower pipelines for their new drug development than they should, and thereby they underspend on research and development. We also present general qualitative insights for one- and two-stage NPD optimal pipeline structures.

UR - http://www.scopus.com/inward/record.url?scp=0036492935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036492935&partnerID=8YFLogxK

U2 - 10.1287/mnsc.48.3.343.7727

DO - 10.1287/mnsc.48.3.343.7727

M3 - Article

AN - SCOPUS:0036492935

VL - 48

SP - 343

EP - 363

JO - Management Science

JF - Management Science

SN - 0025-1909

IS - 3

ER -